CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioCryst Pharmaceuticals, Inc.

BCRX
$2.20BMid Cap

Next catalyst

Phase 3December 2026

navenibart

Hereditary Angioedema (HAE)

Get an email about BCRX's next catalysts

Track BioCryst Pharmaceuticals (BCRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 3Next

navenibart Phase 3 Est. Readout

December 2026~navenibart157

Primary completion for navenibart trial (NCT06842823) in Hereditary Angioedema (HAE)

Source

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)HealthcareπŸ‡ΊπŸ‡ΈNorth AmericaDURHAM450 employees

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

Website

Frequently asked questions

What is in BioCryst Pharmaceuticals, Inc.'s drug pipeline?β†’

CatalystAlert tracks 18 drug candidates in BioCryst Pharmaceuticals, Inc.'s (BCRX) pipeline across Phase 3, Phase 2. Its lead program is navenibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is BioCryst Pharmaceuticals, Inc.'s next FDA catalyst?β†’

BioCryst Pharmaceuticals, Inc.'s (BCRX) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BCRX biotech catalysts?β†’

Add BCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioCryst Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply